In studies of ESCC, however, the rate of HER2 over-expression has been reported to be less than 10 % [8–10] and the efficacy of HER2 targeted drugs in ESCC has not been demonstrated. Here, ERBB2 is linked to esophageal squamous cell carcinoma.